Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Recommendation of "Buy" by Analysts

Quince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) has earned a consensus rating of "Buy" from the seven brokerages that are covering the company, MarketBeat reports. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $8.00.

QNCX has been the subject of a number of research reports. D. Boral Capital reiterated a "buy" rating and issued a $4.00 price objective on shares of Quince Therapeutics in a report on Thursday, July 17th. Wall Street Zen lowered Quince Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd.

Quince Therapeutics Stock Performance

Quince Therapeutics stock remained flat at $1.86 during mid-day trading on Monday. 197,740 shares of the company's stock traded hands, compared to its average volume of 232,774. The company has a current ratio of 4.05, a quick ratio of 4.05 and a debt-to-equity ratio of 0.82. Quince Therapeutics has a twelve month low of $0.51 and a twelve month high of $2.45. The firm has a market capitalization of $84.57 million, a PE ratio of -1.34 and a beta of 0.96. The business's 50 day moving average price is $1.40 and its two-hundred day moving average price is $1.37.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.10). Sell-side analysts predict that Quince Therapeutics will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Quince Therapeutics

Several institutional investors have recently bought and sold shares of QNCX. Virtu Financial LLC purchased a new position in Quince Therapeutics in the 4th quarter worth approximately $55,000. Two Sigma Investments LP purchased a new position in shares of Quince Therapeutics in the fourth quarter worth $57,000. Northern Trust Corp raised its holdings in Quince Therapeutics by 48.5% during the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company's stock valued at $94,000 after buying an additional 16,501 shares during the last quarter. Intellectus Partners LLC bought a new stake in Quince Therapeutics during the 1st quarter valued at $71,000. Finally, Shay Capital LLC boosted its position in Quince Therapeutics by 60.8% during the 4th quarter. Shay Capital LLC now owns 276,799 shares of the company's stock valued at $518,000 after buying an additional 104,616 shares during the period. 30.75% of the stock is currently owned by hedge funds and other institutional investors.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.